Precancerous conditions commonly encountered in clinical practice include monoclonal gammopathy of unknown significance, plasmacytoma, smoldering multiple myeloma, plasmacytoma, myelodysplastic syndrome, among others. The most common conventional approach is watchful waiting given that the few clinical trials have not been successful, or aggressive treatments with limited positive outcomes. Full disclosure, conservative treatments, watchful waiting, and focused nutritional/supplement approaches may have the best outcomes.
January 15, 2025; 1:00 – 2:30 PM EST
Learning Objectives
By the end of this lecture, the clinician will be able to:
- Precancerous conditions-MGUS, SMM, MDS, Plasmacytoma-Diagnostic findings, possible etiologies, possible clinical courses
- Astaxanthin sources and biological activity
- Diversity of K2 and their multiple clinical effects
- Vitamin D role in bone health, multiple myeloma
- Methylsulfonylmethane role in cancer and precancer
CE Credits
CONO: Category A – 1.0 credit (General)
British Columbia: Category C – 1.0 credit
AANP: 1.0 credit (General)
OANP/OBNM: For Oregon attendees seeking OBNM approved CE credits, please note that this event has not been submitted for approval to the OBNM. CE certificate will be issued upon individual request.
Dr Paul Saunders, PhD, ND, RHOM
Dr Paul Richard Saunders is an accomplished professional with dual ND degrees from the Canadian College of Naturopathic Medicine and National College in Portland. His extensive experience spans over 30 years, employing a full range of naturopathic therapies and embracing complex cases. Notable roles at the Canadian College of Naturopathic Medicine include Clinic Director and Associate Dean. Dr. Saunders continues to educate, research, and publish, holding an Adjunct Professorship at National University of Health Science. He is a member of peer-review committees for specialized journals, reviews grant requests for the National Institute of Health (NIH), and was recognized as Ontario Naturopathic Doctor of the Year in 1994 and 2002. He played a significant role in shaping Health Canada’s Office of Natural Health Products and its Expert Advisory Committee.
